Recruitment

Recruitment Status
Completed
Estimated Enrollment
204

Inclusion Criterias

Clinical diagnosis of osteoarthritis
Elected to undergo primary TKA, THA, or TSA
Clinical diagnosis of osteoarthritis
Elected to undergo primary TKA, THA, or TSA

Exclusion Criterias

Previous open hip, knee or shoulder surgery
Patients currently taking opioid pain medication
Patients with severe hepatic disease
...
Previous open hip, knee or shoulder surgery
Patients currently taking opioid pain medication
Patients with severe hepatic disease
Patients with allergies to bupivacaine
Unable to give informed consent
Pre-determined patients discharging to ECF
Patients undergoing simultaneous bilateral joint replacement, as this would require >1 dose of liposomal bupivacaine (Exparel®) per patient for each surgical site
Pregnant or breastfeeding
Non-English speaking
Patients with chronic heart disease as defined as a decreased ejection fraction
Age < 18 years
Patients with contraindication to nerve blocks

Summary

Conditions
  • Osteoarthritis, Hip
  • Osteoarthritis, Knee
  • Osteoarthritis, Shoulder
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Participant)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Liposomal bupivacaine (Exparel®) is a local anesthetic made up of liposomal encapsulated bupivacaine. It is designed to be injected at the time of surgery into the local soft tissues. Because of its unique liposomal delivery system, Liposomal bupivacaine (Exparel®) has been shown to provide up to 96...

Liposomal bupivacaine (Exparel®) is a local anesthetic made up of liposomal encapsulated bupivacaine. It is designed to be injected at the time of surgery into the local soft tissues. Because of its unique liposomal delivery system, Liposomal bupivacaine (Exparel®) has been shown to provide up to 96 hours of pain relief following surgeries. This makes it an attractive option in total joint arthroplasty patients. Combined with the proven efficacy of regional anesthesia, intraoperative liposomal bupivacaine (Exparel®) may provide extended pain relief following total joint arthroplasty. This has the potential to avoid the need for opioid medications. With better pain control, medication side effects can be avoided and patient's length of stay in the hospital can be shortened.

Inclusion Criterias

Clinical diagnosis of osteoarthritis
Elected to undergo primary TKA, THA, or TSA
Clinical diagnosis of osteoarthritis
Elected to undergo primary TKA, THA, or TSA

Exclusion Criterias

Previous open hip, knee or shoulder surgery
Patients currently taking opioid pain medication
Patients with severe hepatic disease
...
Previous open hip, knee or shoulder surgery
Patients currently taking opioid pain medication
Patients with severe hepatic disease
Patients with allergies to bupivacaine
Unable to give informed consent
Pre-determined patients discharging to ECF
Patients undergoing simultaneous bilateral joint replacement, as this would require >1 dose of liposomal bupivacaine (Exparel®) per patient for each surgical site
Pregnant or breastfeeding
Non-English speaking
Patients with chronic heart disease as defined as a decreased ejection fraction
Age < 18 years
Patients with contraindication to nerve blocks

Locations

Columbus, Ohio, 43214
Columbus, Ohio, 43214

Tracking Information

NCT #
NCT02197273
Collaborators
Not Provided
Investigators
  • Principal Investigator: Deborah Napier, BSN,RN,MA OhioHealth
  • Deborah Napier, BSN,RN,MA OhioHealth